GLP-1 Supplemental Training: Keeping Your Knowledge Current in 2026
Dual agonist pharmacology, revised NICE guidance, and changing patient expectations have moved the field on. A short supplemental module closes the gap.
|
£75
Supplemental module price
|
3
Areas that have shifted materially
|
|
2 wks
Typical completion time
|
12 mo
Sensible update cycle
|
A prescriber who completed their weight management training in 2023 is now working with evidence, licensing decisions, and dual agonist pharmacology that barely existed when they qualified. That is the gap GLP-1 supplemental training exists to close.
The field is moving faster than almost any other area of outpatient prescribing, and mid-2026 is a sensible moment to audit what has changed since you last sat formal training. This article covers what has moved, who needs a refresher, and how a short supplemental module keeps your practice aligned with current guidance.
How Much Has Changed Since Your Original Training
Think about the consultation you ran most recently. Did the patient ask about a treatment class, an eligibility rule, or a supply question that did not exist in your original course notes? For most weight management prescribers the honest answer is yes, and the frequency of those moments is the most reliable signal that an update is due.
Three areas have shifted materially. Dual GLP-1 and GIP receptor agonism is now an established treatment class rather than a novelty, with its own efficacy profile, titration schedule, and side effect pattern. NHS commissioning has widened, changing which patients arrive in private clinics and what they already know. And the evidence base on cardiovascular and renal outcomes has matured, reshaping the risk-benefit conversation for several patient groups.
| 2023 |
The single agonist eraMost current prescribers trained when single agonist pharmacology defined the syllabus and dual agonists were still a research story. |
| 2024 |
Dual agonism becomes establishedDual GLP-1 and GIP receptor agonism moved into routine practice, bringing its own titration schedules and side effect patterns. |
| 2025 |
NHS commissioning widensPhased rollout and refined eligibility criteria changed which patients arrive in private clinics and what they already know. |
| 2026 |
Outcome evidence maturesCardiovascular and renal outcome data reshaped the risk-benefit conversation, and monitoring expectations were refined again. |
The NICE guidance on tirzepatide for managing overweight and obesity is a good marker of the pace: eligibility criteria, phased NHS rollout, and monitoring expectations have all been refined since the original recommendations. A prescriber working from memory of older training risks giving patients a picture that is two years out of date.
Patient expectations have shifted alongside the science. People now arrive at consultations having read detailed coverage of trial results, NHS eligibility rules, and supply issues. Answering those questions confidently, and correcting the inaccurate parts gently, requires knowledge that is genuinely current rather than approximately right.
None of this means earlier training was wasted. Foundations in consultation structure, contraindication logic, and patient safety age slowly. What ages quickly is the layer on top: which treatments exist, who qualifies, what the monitoring schedule looks like, and which side effect patterns deserve a faster response.
Who Should Consider GLP-1 Supplemental Training
The module suits three groups. Prescribers who completed a full weight management course more than a year ago and want a structured update. Practitioners who trained on single agonist pharmacology and now see dual agonist patients regularly. And clinicians returning to weight management after time in another specialty, who need the delta rather than the whole syllabus again.
| Completed structured training within the past 12 months | Up to date |
| Trained one to two years ago, seeing GLP-1 patients regularly | Update due |
| Trained on single agonists only, now seeing dual agonist patients | Update overdue |
| Returning to weight management after time in another specialty | Update overdue |
Our GLP-1 and GIP agonist supplemental course is priced at £75 and built precisely for this purpose: a focused update covering the newer pharmacology, revised titration practice, and the counselling points that have changed, without repeating foundations you already hold.
A fourth group is worth naming: pharmacists and prescribers whose employer or insurer has asked for evidence of updated training. Several indemnity providers now look for dated CPD in fast-moving clinical areas, and a certificate from this year carries more weight in that conversation than one from 2023.
What the Supplemental Module Covers
The teaching concentrates on clinical decision-making. You work through comparative pharmacology of single and dual agonists, switching considerations when patients move between treatments, updated contraindication screening, and the management of gastrointestinal side effects across titration. The module also covers the questions patients now arrive with, shaped by news coverage and social media, and how to answer them accurately without overpromising.
Mohammed Ahmad teaches the regulatory thread, drawing on his NHS prescribing background. His sessions track how MHRA safety communications have evolved, and what each update means for day-to-day screening and documentation in a private clinic.
Case discussion runs through the whole module. Rather than presenting pharmacology in the abstract, the teaching works from realistic patient scenarios: the patient switching treatments after a plateau, the patient with worsening reflux at a higher dose, the patient asking why their friend lost weight faster. Each scenario ends with the documentation that should sit in the record afterwards.
Weighing the Cost of an Update Against the Cost of Falling Behind
At £75, the supplemental module sits at the accessible end of the weight loss training pathway, and the pricing is deliberate. An annual update should be an easy decision taken in an afternoon, not a major investment that gets postponed until the knowledge gap becomes uncomfortable in front of patients.
The cost of staying out of date is harder to see on an invoice, but it shows up elsewhere. A consultation that stalls because the patient knows more about a new treatment than the practitioner damages trust that took years to build. Outdated screening or counselling carries clinical risk too, and indemnity providers take a close interest in whether training matches the work actually being done.
There is a quieter commercial cost as well. Patients comparing private clinics increasingly check credentials and recent training before booking, and a visibly current CPD record is one of the few differentiators that costs almost nothing to maintain.
Fitting an Update Into a Busy Summer
Why mid-year works
- Clinic demand softens slightly in late June and July for many practitioners.
- The autumn intake of new patients is still ahead, so the update lands before the rush.
- A completed module gives your CPD record a strong entry before the year tightens.
- The course is online and short enough to finish inside a fortnight around normal working hours.
Treat the booking like a clinic appointment and it will actually happen. Practitioners who block out two or three protected hours a week finish comfortably inside a fortnight, while those who wait for a free weekend tend to still be waiting in September.
Supplemental learning also stacks well with broader development. Practitioners who completed the update often move on to deepen their consultation skills, and the full course catalogue shows how the modules fit together. Whichever route you take, the trainers remain contactable afterwards, so the questions that surface in clinic three weeks later still get answered.
Frequently Asked Questions
What is GLP-1 supplemental training?
It is a short, focused update module for practitioners who already hold weight management training. Rather than repeating foundations, it covers what has changed: dual GLP-1 and GIP agonist pharmacology, revised titration and switching practice, updated screening, and current patient counselling points. It is CPD accredited and produces a certificate of completion.
Do I need to have completed a full course first?
The supplemental module assumes working knowledge of GLP-1 receptor agonists, so it suits practitioners with prior training or current clinical experience in weight management. If you are new to the field, the full GLP-1 Agonists and Weight Management course is the right starting point, and the supplemental module can follow later.
How is dual agonist treatment different from single agonist treatment?
Dual agonists act on both GLP-1 and GIP receptors, which changes the efficacy profile, the titration schedule, and the pattern of gastrointestinal side effects. Switching patients between treatment classes needs specific knowledge around washout, dose equivalence, and expectation setting, which is exactly what the supplemental module works through.
How long does the supplemental course take?
It is deliberately short. Most practitioners complete the online material inside two weeks around normal working hours, and many finish faster. The course costs £75, carries CPD accreditation, and the trainers stay contactable afterwards for the clinical questions that only appear once you apply the material in practice.
Does the module count towards CPD revalidation?
Yes. The course is CPD accredited and generates a certificate suitable for GPhC, NMC, or GDC portfolios. A structured update with a short reflective entry on how it changed your screening or counselling makes a strong revalidation record, particularly when paired with a clear clinical trigger for taking the course.
How often should weight management prescribers refresh their training?
An annual structured update is a sensible benchmark in a field moving this quickly. Licensing decisions, NICE recommendations, and safety communications have all shifted within the past 12 months. Between formal updates, following MHRA drug safety updates and NICE guidance pages keeps the gaps small.
Is the supplemental module relevant for pharmacists as well as prescribers?
Yes. Pharmacists working in or alongside weight management services face the same patient questions and the same pace of change as prescribers. The module covers the counselling, screening, and safety updates that apply across clinical roles, and the CPD certificate supports a GPhC revalidation entry in the same way it does for other registrants.
Keep Your Practice Current
The science will keep moving whether or not your course notes do, and a structured annual update is the simplest way to stay aligned with it. If you are unsure whether the supplemental module or a fuller course fits your starting point, reach the team through our contact page, call 07769 003219, or email info@mjclinicaltraining.co.uk. A two minute description of your current practice is usually enough for an honest recommendation.
A £75 module that keeps you current
CPD-accredited supplemental training on dual agonist pharmacology, switching practice, and updated guidance, taught by practising clinicians.
Last updated: 23 June 2026 by Mohammed Ahmad MPharmS PgDiP PIP and Jella Kang MRPharmS. This article is general professional guidance for clinicians and reflects published guidance at the time of writing.
